RNF166

Across TCGA pan-cancer cohorts, RNF166 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RNF166 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RNF166 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RNF166 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

LUAD, UCEC, and CCRCC are the cancer types where RNF166 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.765	0.440	<.001	29	view →
UCEC	DFS	Median	III,IV	1.000	0.298	.014	18	view →
CCRCC	DFS	Median	II,III,IV	0.921	0.285	<.001	17	view →
LSCC	OS	Median	All	0.921	1.000	.009	16	view →
HNSC	DFS	Median	II,III,IV	0.842	1.000	.006	12	view →
GBM	OS	Quartile	All	0.918	0.711	.010	6	view →
PDAC	OS	Quartile	III,IV	1.000	0.358	.036	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RNF166–LUAD (DFS)

Open the LUAD breakdown →